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Edited by Jesus AvilaAbstract Murine brain-speciﬁc angiogenesis inhibitor 1 and 2
(mBAI1, mBAI2) are involved in angiogenesis after cerebral
ischemia. In this study, mBAI3 was cloned and characterized.
Northern and Western blot analyses demonstrated a unique
developmental expression pattern in the brain. The level of
mBAI3 in brain peaked 1 day after birth, unlike mBAI1 and
mBAI2, which peaked 10 days after birth. In situ hybridization
analyses of the brain showed the same localization of BAI3 as
BAI1 and BAI2, which includes most neurons of cerebral cortex
and hippocampus. In the in vivo focal cerebral ischemia model,
BAI3 expression decreased from 0.5 h after hypoxia until 8 h,
but returned to control level after 24 h. The expression of
vascular endothelial growth factor following ischemia showed an
inverse pattern. The decreased expressions of BAIs in high-grade
gliomas were observed, but BAI3 expression was generally lower
in malignant gliomas than in normal brain. Our results indicate
that the expression and distribution of BAI3 in normal brain, but
not its developmental expression, are very similar to those of
BAI1 and BAI2, and that BAI3 may participate in the early
phases of ischemia-induced brain angiogenesis and in brain
tumor progression.
 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Recently, human BAI1 (hBAI1), a novel brain-speciﬁc gene,
was isolated by the strategy of identifying genomic DNA
fragments containing functional p53 binding sites [1]. The
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doi:10.1016/j.febslet.2004.06.0111, a protein related to the Refsum disease gene product, was
found to interact with the cytoplasmic region of hBAI1
through yeast two-hybrid screening, and we cloned the murine
BAI1 homologue (mBAI1) [2]. The seven-span transmembrane
region (STR) and two functional elements, an Arg-Gly-Asp
(RGD) motif and thrombospondin type 1 repeats (TSRs) are
well conserved between hBAI1 and mBAI1. The TSR can in-
hibit experimental angiogenesis induced by basic ﬁbroblast
growth factor in the rat cornea [3], and also is present in sev-
eral proteins involved in the guidance of nerve growth cones
and axonal growth, such as UNC-5 and F-spondin [4].
Two novel human genes homologous to hBAI1 have been
identiﬁed and designated as hBAI2 and hBAI3. Analysis of
their predicted proteins shows that the TSR and STR are well
conserved among the three BAIs. Like hBAI1, the other two
genes are speciﬁcally expressed in brain and it appears likely
that the three hBAIs are closely related. However, the extra-
cellular and cytoplasmic domains are relatively diﬀerent
among them [5]. In a study using the rat focal cerebral ische-
mia injury model produced by the occlusion of the middle
cerebral artery, we showed that the expression of BAI1 de-
creased on the ischemic side [2]. Also, we showed that BAI2
is involved in ischemia-induced brain angiogenesis [6]. To
date, the functions of neuron-speciﬁc BAI3 in the brain are
unknown.
Glioblastoma is a highly vascularized and high-grade solid
tumor of the central nervous system. Angiogenesis is a
prominent feature of glioblastoma but the mechanisms in-
volved in the control of this process are not completely un-
derstood [7]. The angiogenic factors that have been implicated
in glioma angiogenesis are vascular endothelial growth factor
(VEGF) and basic ﬁbroblast growth factor. Hypoxia-inducible
factor 1a (HIF-1a) initiates the transcription of a number of
hypoxia-inducible genes including VEGF [8]. Recently, it was
reported that the expression of BAI1 is absent in most glioma
cell lines and in most human glioblastomas [9]. However, the
expression of the other two BAI genes and their relevance in
the progression of glioma were not reported.
In this study, we cloned mouse BAI3 and investigated its
expression and distribution in the brain. We examined the
angiostatic characteristics of BAI3 in the rat focal cerebral
ischemia injury model, and also examined whether the ex-
pression of the three BAIs and certain angiogenic factors were
changed in diﬀerent grades of human glioma. We found thatblished by Elsevier B.V. All rights reserved.
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pates in the regulation of ischemia-induced brain angiogenesis
and in the progression of glioma.2. Materials and methods
The investigation conforms to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of Health
(NIH Publication No. 85-23, revised 1996). The Ethics Committee of
Chonnam National University Medical School approved all experi-
mental protocols, including the use of surgically resected specimens.
2.1. Tumor samples
All tumor specimens were obtained from patients undergoing ther-
apeutic operation for brain tumors at Chonnam University Hospital
(Kwangju, Korea) from 2000 to 2003. All glioma samples were clas-
siﬁed according to the World Health Organization classiﬁcation of
brain tumors (low-grade, grade III, and grade IV). The low-grade
glioma used consisted of 1 pilocytic astrocytoma (patient #1), 1 as-
trocytoma (patient #2), 1 astrocytoma of grade II (patient #3), 2
ependymomas (patients #4 and #5), and 1 oligodendroglioma of grade
II (patient #6). Grade III tumors consisted of 2 anaplastic mixed gli-
omas (patients #7 and #8), 2 anaplastic ependymomas (patients #9
and #10), 2 anaplastic oligodendrogliomas (patients #11 and #12).
Grade IV tumors consisted of 4 glioblastomas (patients #13–16).
Normal brain tissue was obtained from 1 patient with head trauma
from a traﬃc accident.
2.2. Isolation of murine BAI3 cDNA
A murine cDNA spanning nucleotides 3868 through 4391 was gen-
erated by RT-PCR using oligonucleotides based on the human se-
quence [5]. Total RNA from mouse brain (400 ng) was used as the
template. The human sense and antisense primers were 50-AGA-
GGGGCTGACATGGACATAG-30 and 50-GCAGGGTTTTCCA-
TACTGCTTG-30, respectively. The resulting 524-bp product was
subcloned into the TA vector cloning system (Invitrogen), and the
identity of the cDNA was conﬁrmed by sequencing. The GenBank
BLAST homology-search program was used to search for this se-
quence. The cDNA insert corresponded to the cytoplasmic region of
mBAI3. This cDNA fragment was then used to screen the mouse brain
lambda ZAP II cDNA library to obtain the full-length cDNA of
mBAI3 (Fig. 1). The mBAI3 cDNA has been deposited in the Gen-
Bank database (NM 175642).
2.3. Northern blot and RT-PCR analyses
Total RNAs were extracted from the mouse (BALB/c) tissues, and
normal or ischemic mouse brain tissues, and tumor tissue of each
glioma patient as described [10]. For Northern analysis, total RNA (10
lg) was denatured with glyoxal, separated by size on 1.0% agarose
gels, and transferred to Genescreen (Dupont). Probes (mBAI3, nu-
cleotide residues 3661–4056) were radiolabeled by nick translation, and
hybridization and signal visualizations were performed as described
[10]. In all experiments, the integrity of the RNA samples was estab-
lished by Northern analysis with a mouse b-actin or GAPDH probe.
The intensity of the bands was quantiﬁed by imaging densitometry
with the Gel Documentary System (DOC 2000 model, Bio-Rad), and
each transcript level of BAI was normalized with respect to the cor-
responding GAPDH level.
Reverse transcription was performed at 42 C for 60 min (200 ng of
total RNA, 100 pmol random primers, reverse transcriptase). The RT-
PCR exponential phase was determined to be 30 cycles to allow quan-
titative comparisons among the cDNAs from identical reactions.
Cycling conditions were: initial denaturation at 94 C for 5min followed
by 30 cycles at 94 C for 1 min, appropriate annealing temperature for 1
min, and 72 C for 2 min (Mastercylcer Personal PCR system, Eppen-
dorf). The annealing temperature was 60 C formBAI3 and b-actin. The
ampliﬁcation products were analyzed on agarose gels and visualized by
UV epiﬂuorescence following ethidium bromide staining. Also, RT-
PCR was performed with primers for b-actin as a control. PCR primers
were as follows: sense, 50-GAATTTGGAATGATGGGAGATC-30 and
antisense, 50-GATAATCCTCTGGGCATATTTC-30 for TSR of
mBAI3; sense, 50-CTCTAT-GCCTTCGTTGGACCTG-30 and anti-
sense, 50-CATGGCCAGAACTGCAGACATC-30 for third loop ofSTR in mBAI3; sense, 50-GATGATATCGCCGCGCTCGTC-30
and antisense, 50-AGCCAGGTCCAGACGCAGGAT-30 for mouse
b-actin.
To investigate the expression level of anti-angiogenic factors (BAI1,
BAI2, BAI3, TSP1), angiogenic factors (VEGF, HIF-1a), and the p53
gene in human glioblastoma, we also employed an RT-PCR assay. PCR
primers were as follows: sense, 50-ATGACCGACTTCGAGAAG-
GACG-30 and antisense, 50-TCTGCGGCATCTGGTCAATGTG-30
for hBAI1; sense, 50-GTGTCCAGCCTTCCATGAGATG-30 and an-
tisense, 50-TTTCCGCATCCACCATGAAGC-30 for hBAI2; sense,
50-GAATTTGGAATGATGGGAGATC-30 and antisense, 50-GATA-
ATCCTCAGGGCATATTTC-30 for hBAI3; sense, 50-CGTCCTGTT-
CCTGATGCATG-30 and antisense, 50-GGCC-CTGTCTTCCTGC-
ACAA-30 forhTSPl; sense, 50-TGCCATCCAATCGAGACCCTG-30 and
antisense, 50-ATCTGGTTCCCGA-AACGCTGAG-30 for hVEGF;
sense, 50-AAGCCCTGAAAGCGCAAGTCC-30 and antisense,
50-TG-CATGATCGTCTGGCTGCTG-30 for hHIF-1a; sense, 50-AA-
GCAATGGATGATTT-30 and antisense, 50-AGCTGTTCCGTCC-
CAGTAGA-30 for p53. RNA integrity was conﬁrmed with parallel
RT-PCR ampliﬁcation using b-actin primers.
2.4. Production of the anti-mBAI3 antibody and Western blot analysis
A GST-mBAI3 fusion construct was prepared by amplifying the
nucleotide residues 3661–4056 (a region unique to mBAI3) of murine
BAI3. The fragment was cloned into the unique BamHI and EcoRI
sites of pGEX-2T and puriﬁed as previously described [2]. Rabbit
polyclonal antiserum recognizing mBAI3 was prepared using the GST-
mBAI3 fusion protein. The serum recognizing mBAI3 was passed
through a column of GST-mBAI3 fusion protein, and the column was
eluted with a low-pH buﬀer to obtain the anti-GST-mBAI3 antibody.
The eluate was further puriﬁed by passage through a column of GST
protein to remove the anti-GST antibody component. Cell lysates were
prepared from mouse tissues using a lysis buﬀer containing 1% Triton
X-100, and resolved by SDS–PAGE. Resolved proteins were trans-
ferred to a nitrocellulose membrane and blotted with anti-BAI3 serum
and anti-rabbit Ig-HRP (Ammersham) as previously described [10].
The intensity of the bands was quantiﬁed by imaging densitometry
with the Gel Documentary System (DOC 2000 model), and each
protein level of BAI3 or VEGF was normalized with respect to the
corresponding actin level.
2.5. In situ hybridization
Sprague–Dawley rats (200–230 g) were anesthetized with an intra-
peritoneal injection of sodium pentobarbital (50 mg/kg), and the brain
was ﬁxed by in vivo perfusion of the abdominal aorta with 4% para-
formaldehyde in a phosphate buﬀered saline (PBS) for 10 min. The
brain was excised and then immersed in the same ﬁxative for 3 h at
4 C. The tissue blocks were washed in PBS, dehydrated in a graded
series of ethanol washes, and embedded in paraﬃne. Tissue sections
were cut at 6 lm and mounted on gelatine-coated glass slides. Sense
and anti-sense probes speciﬁc for the mBAI3 were generated from the
recombinant plasmid (nucleotides 3661–4056), using T3 and T7 RNA
polymerases in the presence of digoxigenin-11-UTP (Boehringer
Mannheim). In situ hybridization was performed as described previ-
ously [2]. Brieﬂy, the tissue sections were deproteinated and acetylated.
Prehybridization was conducted at 48 C for 4 h in a humidiﬁed
chamber. The slides were then hybridized with 20 ng/ll digoxigenin-11-
UTP-labeled riboprobe in a hybridization buﬀer at 48 C for 14–16 h.
Hybridizations with the sense probes were performed in parallel with
the anti-sense probes on adjacent sections. Unbound probe was re-
moved by sequential washes of SSC with or without 20 lg/ml ribo-
nuclease. RNA–RNA hybrids were immunodetected with a 1:500
dilution of anti-digoxigenin alkaline phosphatase conjugate, followed
by incubation with nitro blue tetrazoliurn salt and 5-bromo-4-chloro-
3-indolyl phosphate. After mounting in a crystal mount medium, the
sections were photographed on a light photomicroscope.
2.6. Focal ischemia model in rat
Sprague–Dawley rats (200–230 g) were anesthetized with 4% halo-
thane in an anesthetic chamber and maintained with 1% halothane in
100% O2 using a rodent mask. Operation for focal ischemia was per-
formed as described previously [6]. Brieﬂy, the right common carotid
artery (CCA) was exposed and then the external carotid artery (ECA)
was transected 2 mm distal from the carotid bifurcation after being
ligated by 4-0 silk suture. The internal carotid artery (ICA) was then
Fig. 1. Deduced amino acid (aa) sequence of mBAI3 compared with mBAI1 and mBAI2. The mBAI2 and mBAI3 sequences are shown below the
mBAI1 sequence. The gaps introduced for maximal alignment are marked with dashes. mBAI3 is a 1522-aa protein (4569-bp transcript) with a
deduced molecular mass of 171-kDa. Thrombospondin type I repeats (TSR) and seven-span transmembrane regions (STR) are indicated in open and
ﬁlled box, respectively. The aa in the TSR and STR are well conserved among them. GPS (G protein-coupled receptor proteolysis site) domain is
represented by italic characters in the open box just before the STR region. The third cytoplasmic loop of STR, which is deleted in the splice variant
of mBAI3 (mBAI1-DSTR) is represented by bold italic characters in the ﬁlled box.
H.J. Kee et al. / FEBS Letters 569 (2004) 307–316 309isolated. The CCA and ICA were occluded with microvascular clips. A
3-cm length of 4-0 monoﬁlament suture with a slightly enlarged tip was
introduced into a hole in the ICA, and then the microvascular clip inthe ICA was removed. The suture was then gently advanced about 18
mm into the ICA and circle of Willis to cross the opening of the middle
cerebral artery. The rat was sacriﬁced after the time course of ischemia
310 H.J. Kee et al. / FEBS Letters 569 (2004) 307–316(0.5, 2, 4, 8, 24 h), and the brain was exposed. Brain slices were stained
with 2% triphenyl tetrazolium chloride to visualize and measure the
infarct volumes in each group [2]. The ischemic portion of the cerebral
cortex and the contralateral portion of the normal cerebral cortex were
removed for protein preparation.3. Results and discussion
3.1. Cloning of the murine BAI3 cDNA
A set of oligonucleotide primers capable of amplifying the
unique cytoplasmic region of the human BAI3 transcript was
used to amplify the corresponding region of the murine BAI3
mRNA. The resulting 524-bp ampliﬁcation product was sub-
cloned and sequenced to conﬁrm its identity (nucleotides 3868–
4391 of mBAI3). This fragment was then used to screen a
mouse brain lambda ZAP II cDNA library and several positive
clones were obtained. Database searches with the deduced
amino acid sequence identiﬁed a high degree of identity
(92.5%) between one of positive clones (#104) and hBAI3. This
murine cDNA fragment was then used to rescreen the mouse
brain cDNA library, and several clones (#101, #107, #109)
were isolated (data not shown). Clone 107 had start codon,
and clone 109 had a stop codon. The overlapping clones
spanned a total of 4597 bp.
Sequence analysis of the cDNA identiﬁed an open reading
frame that could direct the synthesis of a protein of 1522
amino acids (aa), with a calculated molecular mass of 171 kDa.
The termination codon of the open reading frame was located
at nucleotides 4567–4569. Database surveys identiﬁed a high
degree of deduced amino acid sequence identity (98.4%) be-
tween this cloned gene product and hBAI3 over the full lengthFig. 2. Schematic representation of the conserved domain in mBAI3 protein
TSRs, a GPS domain in the extracellular region, and an STR, suggesting tha
glycoconjugate-binding motif together with ﬂanking sequences from 4 TSRs
mBAl2. WSXW is underlined, CSVTCG is boxed, CSXTCXXXXXXRXR isof the molecule. Based on this high degree of homology, we
identiﬁed our cloned gene product as murine BAI3. The de-
duced amino acid sequences of the mBAI3, mBAI2 and
mBAI1 genes are shown in Fig. 1. The TSR in the extended
extracellular domain and the STR are located at the same
positions and highly conserved among them. However, the
cytoplasmic region (1262–1371 aa) of mBAI3 was divergent
from that of mBAI2 (1311–1416 aa) and mBAI1 (1299–1371
aa) genes (Fig. 1). This divergence indicates that BAI-inter-
acting proteins that bind to this cytoplasmic region might
diﬀer among the three proteins. The presence of alternative
splicing in the third cytoplasmic loop of the STR was con-
ﬁrmed by RT-PCR (Fig. 4G).
The predicted structure of the mBAI3 protein includes ex-
tended extracellular and cytoplasmic domains, a GPS (G
protein-coupled receptor proteolysis site) domain, and an STR
(Fig. 2A). The STR (748–1176 aa) and Latrophilin/CL-1-like
GPS domain were present in mBAI3, as in mBAI1 and
mBAI2. Thus, mBAI3 was assumed to be a G-protein coupled
receptors (GPCRs) in the brain having a GPS domain and
STR. mBAI3 has 4 TSRs, as does mBAI2, while mBAI1 has 5
TSRs, though the functional signiﬁcance of this diﬀerence is
unknown. The conserved domains observed in mBAI3 give
some indication of its possible function. Thrombospondin-1
(TSP1) and thrombospondin-2 (TSP2), two TSR-containing
proteins of the TSP family, possess antiangiogenic activity
[11,12]. In contrast, thrombospondin-3, which lacks TSRs, has
no inhibitory activity on human dermal microvascular endo-
thelial cell (EC) proliferation, conﬁrming that TSRs elicit the
antiangiogenic activity of TSP1 and TSP2 [13]. The TSR
contains two subdomains that may independently inﬂuence theand comparison of cell-binding motifs among BAIs. (A) mBAI3 has 4
t BAI3 may be a G-protein-coupled receptor in the brain. (B) The cell/
of mBAI3 is aligned with the corresponding sequences of mBAI1 and
drawn with a dotted line, and BBXB is represented with a broken line.
Fig. 3. Northern and Western blot analyses of mBAI3 expression in
various mouse tissues. Total RNA isolated from various tissues of 18-
day embryonic (A) and 3-month-old adult (B) mice was hybridized
with an mBAI3 cDNA probe. For each blot, RNA ﬁdelity was con-
ﬁrmed by rehybridization with a b-actin probe (lower panels). Note
that the 6.0-kb transcript was only expressed in brain of both em-
bryonic (A) and adult (B) tissues. (C) Total tissue protein was isolated
from various tissues of adult mice and reacted with polyclonal anti-
body against mBAI3. An upper thick arrow indicates the 177-kDa
mBAI3 protein, which shows a brain-speciﬁc expression pattern. PC12
cell, treated with neuronal growth factor (150 ng/ml) for 5 days to
diﬀerentiate into neuronal cells and have the neuronal characteristics,
was added as a positive control for the neuronal expression of BAI3.
There was other lower band (172 kDa band, lower thin arrow) in the
brain, lung, skeletal muscle and testis recognized by a polyclonal anti-
mBAI1 antibody. The molecular mass marker is shown on the left. The
same blot was reprobed with anti-actin antibody to control for loading
(lower panel).
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from the TSR have been found to have potent antiangiogenic
activity in vivo and in assays of EC function [3,14].
The WSXW and CSXTCXXXXXXRXR motifs were found
in 3 TSRs, but not the fourth TSR, in all 3 mBAIs (Fig. 2B).
Actually, mBAI1 has another TSR before 1st TSR, but it is not
shown in Fig. 2B. The CSVTCGmotif was identiﬁed in the ﬁrst
TSR of mBAI3 (Fig. 2B). It has been reported that the WSXW,
CSXTCXXXXXXRXR, and CSVTCG motifs are involved in
cell binding [4]. In the fourth TSR of the three mBAIs, a BBXB
motif (B representing a basic aa residue) is present instead of a
WSXWmotif (Fig. 2B). BBXB, located adjacent to the WSXW
motif, is also a cell-binding motif. Previous studies showed that
the peptide sequence CSVTCG within the TSR of TSP1 in-
teracts with a surface receptor glycoprotein, CD36 [15]. The
CSVTCG peptide mediates the in vitro and in vivo inhibitory
eﬀects of TSP1 on ECs [12,16]. The ﬁrst TSR of BAI3 may be
important to antiangiogenic activity because it contains a
CSVTCG motif for CD36 binding. mBAI3 also has CSFTCG
(2nd TSR) and CSVTCS (3rd TSR) sequences, similar to the
CSVTCG motif. Properdin, which has 6 TSRs, plays an im-
portant role in full complement activity [17]. However, pro-
perdin lacking the fourth TSR, which contains the sequence
CPVTCG, is unable to stabilize the alternative pathway C3
convertase [18]. Using the NCBI conserved domain search, we
also found that the 4 TSR domains of mBAI3 align well with
spondins, serine proteinase inhibitor with TSRs, and disinte-
grin metalloproteinases with TSRs.
The GPS domain consists of about 50 aa residues, including
4 cysteine residues and 1 cleavage site, in all homologous
GPCRs, the GPS domain is located in the extracellular portion
of the receptors immediately adjacent to the ﬁrst transmem-
brane segment [19,20]. The GPS domain contains a putative
proteolytic site that appears to be conserved in a number of
homologous adhesion GPCRs; the cleavage sites for the ex-
tracellular portion of the receptors are located in the C-ter-
minal amino acid residues of the GPS, although this region is
poorly conserved among GPCRs [21]. In mBAI1, the putative
proteolytic site is located in the extracellular portion before the
ﬁrst transmembrane region (CXCXXLST, aa 921–928). Re-
cently, we found that BAI1’s extracellular region is cleaved at
three sites, and one of the cleaved fragments (BAI1-TSR) is the
core extracellular fragment for BAI1’s anti-proliferative ac-
tivity, which is derived from the functional blocking of avb5
integrin in ECs [22]. Because mBAI3 also contains a GPS
domain like mBAI1, the extracellular portion of mBAI3 may
also be cleaved at the TSR-containing regions or GPS domain.
3.2. Brain-speciﬁc expression pattern of mBAI3
A Northern blot tissue survey was performed using an
mBAI3 cDNA probe (nucleotides 3661–4056) to ascertain the
developmental pattern of mBAI3 expression. A 6.0-kb tran-
script was observed only in brain of embryonic day 18 mouse
tissues (Fig. 3A, upper panel). Most adult (3 months old) tis-
sues expressed little or none of the 6.0-kb transcript, although
a very high level was detected in the brain (Fig. 3B, upper
panel). These results indicate that mRNAs encoding mBAI3
are the most abundant in brain regardless of developmental
stages and are not expressed in other tissues. It is of interest to
note that mBAI3 genes showed a more brain-speciﬁc expres-
sion pattern than mBAI2 and mBAI1, because mBAI3 has not
expressed in other tissues even in the embryonic period.To monitor the brain-speciﬁc expression pattern of mBAI3,
Western blot analysis of tissue distribution was performed
using a polyclonal anti-mBAI3 antibody raised against amino
acids 1221–1352 of mBAI3 fused to GST. This region is lo-
calized in the unique cytoplasmic portion of mBAI3. Only the
brain expressed the BAI3 protein, which appeared as a 177
kDa band (Fig. 3C, upper thick arrow). However, there were
other lower bands (172 and 162 kDa band) in the brain,
lung, skeletal muscle and testis recognized by a polyclonal anti-
mBAI3 antibody. Especially, prominent band (172 kDa,
Fig. 3C, lower thin arrow) may result from alternatively
spliced variant of mBAI3, which was devoid of third loop of
STR. However, this spliced transcript was not observed in the
Northern blot assays because the diﬀerences of molecular size
between the wild-type BAI3 and variants were relatively small,
and the Northern message of mBAI3 was a little thick.
3.3. The developmental expression pattern of mBAI3 in the
brain
To further characterize the developmental expression pat-
tern of mBAI3 in the brain, RNAs were prepared from brains
Fig. 4. Developmental expression pattern of mBAI3 in the brain. Total
mouse brain RNA from various stages of development was hybridized
with a cDNA probe for mBAI3 (A), mBAI2 (B) or mBAI1 (C). For
each RNA blot, RNA ﬁdelity was conﬁrmed by rehybridization with a
b-actin (D) and GAPDH (E) probes. (F) Densitomeric analyses of
Northern blot for BAI1, BAI2 and BAI3. Each BAI level was nor-
malized with respect to the corresponding GAPDH level. The ex-
pression level of mBAI3 reached its highest level at 1 day after birth
(PN1). However, the expression of mBAI3 decreased continuously
after the early neonatal period through adulthood. In contrast, the
expression levels of mBAI2 and mBAI1 increased after birth and
reached their highest levels at 10 days (PN10). E18, embryonic day 18;
PN1, PN3, PN10, PN15, PN22, PN29; neonatal days 1, 3, 10, 15, 22,
29 after birth. (G) RT-PCR analyses of developmental expression of
alternatively spliced variants of mBAI3 in the brain. The wild-type
mBAI3 with TSR and STR showed the highest level during the neo-
natal period. mBAI3 did not have any TSR deletion, but did have an
STR-deleted sequence (mBAI3-DSTK). The 313-bp product corre-
sponds to the wild-type sequence of mBAI3, and the 214-bp band
corresponds to the product (mBAI3-DSTR) lacking the third loop of
STR. Emb, embryonic day 18; Neo, neonatal day 1; Ad, 3 months old.
(D, H) High levels of b-actin in the embryonic and early neonatal
brains reﬂect the high cellular activities in these periods.
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3 after birth), before and after eyelid opening (neonatal days
10, 15, 22, 29), 8 weeks, and 3 months old. The expression level
of mBAI3 increased after birth and reached its highest level
during the early neonatal period. After 10 days, it decreased
continuously until adult life (Fig. 4A and F). However, unlike
to that of mBAI3, the expression of mBAI2 or mBAI1 reached
its highest level after 10 days, but it decreased slightly after
15 days, and this level was maintained in the adult (Fig. 4B, C
and F).
We performed RT-PCR analyses using speciﬁc primers
ﬂanking the TSRs and STR to investigate whether mBAI3, like
mBAI2, has any alternatively spliced variants and to examine
the developmental expression of any spliced variants in mouse
brain. Unlike mBAI2, mBAI3 had no alternatively spliced
variants of the ﬁrst TSR- and/or second TSR during brain
development of brain (Fig. 4G). However, RT-PCR analyses
of adult brain RNA using primers ﬂanking the third cyto-
plasmic loop of the STR produced 314- and 214-bp ampliﬁ-
cation products corresponding to the wild-type and a deleted
sequence lacking the third loop, respectively. The identities of
these RT-PCR products were conﬁrmed by sequence analysis.
In agreement with the Northern blot results, RT-PCR
analyses showed that the expression of mBAI3 was a little
higher in the neonatal period than in the embryo or adult
during the development of brain. However, the expression of
the spliced variants lacking the third cytoplasmic loop was
higher in embryonic brain than in neonatal or adult brain.
These results indicate that alternative splicing produces a
variant of mBAI3 lacking the third loop of the STR, but de-
velopmental expression of this variant in the brain is diﬀerent
from that of the spliced variants of mBAI2, which showed the
same expression level from embryonic to adult brain [6]. The
third cytoplasmic loop is important for the interaction of G
protein in the serpentine receptors coupled to G proteins,
which have STR [23]. Thus, the spliced variant of mBAI3,
which did not have this third loop, may not perform certain
essential functions of wild-type mBAI3. We are currently using
yeast two-hybrid assay to search for G-proteins or other
proteins that interact with this cytoplasmic loop. When con-
sidering that mBAI3 has several cell-binding motifs and
mBAI3 is expressed at its highest level during the early neo-
natal period, but decreases continuously until adult life, we
speculate that mBAI1 acts as an early antiangiogenic factor in
the development of brain among the three BAIs.
3.4. Localization of BAI3 mRNA in the brain and
developmental expression of BAI3 in the cerebral cortex
To determine the expression pattern of BAI3 in the rat
brain, in situ hybridization analysis was performed with an
antisense riboprobe spanning nucleotides 3661 through 4056,
which is a BAI3-speciﬁc region. BAI3 was expressed
throughout most neurons of the whole cerebral cortex, but a
high level was present in layers II–III and IV just as it is for
BAI1 or BAI2 (Fig. 5A and B). It was also present in high
levels in the pyramidal neurons of all ﬁelds of the hippocam-
pus, and the granule cell and polymorphic layers of the dentate
gyrus (Fig. 5A and C). In the cerebellum, the BAI3 signal was
most abundant in the Purkinje cell layer, but diﬀuse and very
weak signals were observed in the granular and molecular
layers, respectively (Fig. 5D). BAI3 was also expressed in
several nuclei of the brain stem (Fig. 5A). It was highly ex-pressed in the hypoglossal (Fig. 5E), trigeminal motor and
sensory (Fig. 5F), cochlear (Fig. 5G). It was also expressed in
the pontine reticular nucleus and reticular part of substantia
nigra (Fig. 5A). These observations indicate that, like BAI1
Fig. 5. In situ hybridization localization of BAI3 mRNA in several regions of adult rat brain and in several nuclei of brain stem. (A) Localization of
BAI3 mRNA (upper) in the adult rat brain. Digoxigenin-labeled antisense BAI3 probe was hybridized under stringent conditions to a horizontal
section of brain (upper panel). Camera lucida drawing showing the labeled structures in the rat brain (lower panel). 3V, third ventricle; 6, abducens
nucleus; 12, hypoglossal nucleus; Acb, accumbens nucleus; AH, anterior hypothalamic area; CA1, CA2, CA3; CA1, CA2, CA3 ﬁeld of Ammon’s
horn; DG, dentate gyrus; Ent, entorhinal cortex; LH, lateral hypothalamie area; LV, lateral ventricle; mcp, middle cerebellar peduncle; mlf, medial
longitudinal fasciculus; Mo5, motor trigeminal nucleus; PCRt, parvocellular reticular nucleus; Pir, piriform cortex; PnO, oral pontine reticular
nucleus; Pr5DM, dorsomedial principal sensory trigeminal nucleus; Pr5VL, ventrolateral principal sensory trigeminal nucleus; S, subiculum; SI,
substantia innominata; SNR, substantia nigra reticular part; sp5, spinal trigeminal tract; Sp5C, caudal spinal trigeminal nucleus; Sp5I, interpolar
spinal trigeminal nucleus; Sp5O, oral spinal trigeminal nucleus; STh, subthalamic nucleus; Th, thalamic nucleus; VCA, anterior ventral cochlear
nucleus; VCP, posterior ventral cochlear nucleus; Vp, ventral pallidum; VTA ventral segmental area. (B) Perirhinal cortex showed strong hybrid-
ization signals in most neurons of layers II through VI. (C) Pyramidal neurons of all ﬁelds (CA1, CA2, CA3) of Ammon’s horn, and the granule cell
and polymorphic layers of dentate gyrus (DG) showed high hybridization signals. (D) Cerebellar cortical sections showing strong signals in the
Purkinje cells, but diﬀuse weak signals in the granular layers (G) and very weak signals in the molecular layers (M). (E) Strong hybridization signals
were found in the large neurons of the hypoglossal nucleus. (F) Signals were detected in the interpolar spinal trigeminal nucleus. (G) Very strong
signals were detected in the anterior and posterior ventral cochlear nucleus. Scale bars (A), 500 lm; (B–G), 200 lm.
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Fig. 6. Developmental expression of BAI3 in cerebral cortex. Cerebral cortex of the rat brain was hybridized digoxigenin-labeled sense (A, 2 weeks,
negative control) and antisense BAI3 probe (B, C, D) at time points after birth (2, 3 and 8 weeks). (B) At 2 weeks, a high activity of the BAI3 was
detected throughout the whole cerebral cortex. (C) At 3 weeks, the expression level of the BAI3 decreased slightly in the whole cerebral cortex. (D) At
8 weeks, the expression level of the BAI3 decreased generally in the whole cerebral cortex, but it showed a relative strong hybridization signal in most
neurons of layers II–III. Scale bar, 50 lm.
Fig. 7. Western blot analysis of BAI3 in ischemic cerebral tissues. (A)
Expression of BAI3 (arrow) decreased in the ischemic side at 0.5 h
after ischemia until 8 h compared with sham-operated cerebral cortex
(Control), but returned slowly to its basal level after 24 h. (B) VEGF
increased at 0.5 h, peaked at 8 h, and returned to its basal level at 24
h. (C) The same blot was reprobed with anti-actin antibody to
control for loading. The molecular mass marker is shown on the left.
(D) Densitomeric analyses of Western blot for BAI3 and VEGF.
BAI3 or VEGF level was normalized with respect to the corre-
sponding actin level. The reported values are the means S.E.M. of 3
observations. Signiﬁcance of diﬀerence of relative BAI3 or VEGF
level (ratio of BAI3 or VEGF versus actin densitometric value) in
each period compared with control one was tested by Student’s t-test
(**P < 0:01; ***P < 0:001).
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calization of BAI3 expression in the brain coincides with that
of BAI1 or BAI2.
To conﬁrm the Northern data that the neonatal brain has
higher levels of BAI3 expression than the adult, in situ hy-
bridization experiment was performed to the neonatal cerebral
cortex of 2, 3 and 8 weeks-old brain (Fig. 6). At 2 weeks, a high
activity of the BAI3 was detected throughout the whole cere-
bral cortex (Fig. 6B). BAI3 decreased slightly in the whole
cerebral cortex at 3 weeks (Fig. 6C), but decreased generally at
8 weeks (Fig. 6D). However, it showed a strong hybridization
signal in most neurons of layers II–III at 8 weeks. These results
indicate that BAI3 was highly expressed in neonatal brain, and
it was derived from neuron-speciﬁc expression, but not from
the result of glial expression of BAI3.
3.5. Changes in BAI3 expression in focal ischemia
To investigate the role of BAI3 in ischemia-induced brain
angiogenesis, the temporal expression proﬁles of BAI3 and
VEGF in ischemic cerebral tissues were measured in the in vivo
focal cerebral ischemia model. Western blot analyses of the
ischemic portion of the cerebral cortex using speciﬁc anti-
bodies recognized 170- and 25-kDa bands corresponding
to BAI3 and VEGF proteins, respectively. The expression of
BAI3 decreased on the ischemic side of the brain at 0.5 h after
ischemia until 8 h, compared with sham-operated cerebral
cortex, but it slowly recovered by 24 h (Fig. 7A). BAI3 level
was signiﬁcantly decreased throughout all experimental peri-
ods compared with that of control (Fig. 7D). The level of
VEGF expression was transiently increased in the ischemic
cortex at 0.5 h, peaked at 8 h, and it returned to basal level at
24 h after ischemia (Fig. 7B). VEGF level was signiﬁcantly
increased at 8 h compared with that of control (Fig. 7D).The ischemic brain might stimulate angiogenesis to com-
pensate for impaired circulation. TSP1 and TSP2 are naturally
occurring angiostatic factors that inhibit angiogenesis in vivo
and in vitro. The roles of TSP and BAIs in the regulation of
postischemic angiogenesis are not completely known. Re-
Fig. 8. RT-PCR analyses of angiostatic (BAI1, BAI2, BAI1, TSPl) and
angiogenic (VEGF and HIF-1a) genes in human gliomas. Expression
was examined in various grades of gliomas by RT-PCR analyses of 17
human brain samples. (A) The expression of BAI1 was observed in
most human gliomas except 3 cases of ependymomas (#4 and #5
ependymomaa and #9 anaplastic ependymoma). (B) The expression of
BAI2 was reduced in all grade III samples compared to normal brain
tissue, though the diﬀerence was small. (C) The expression of BAI3
decreased in grade III and IV gliomas. In particular, BAI3 was barely
detectable in ependymoma (#4) and anaplastic ependymoma (#9).
Normal brain and low-grade glioma did not express VEGF (D) or
HIF-1a (E) except ependymomas (#4 and #5), and VEGF expression
was almost exclusively observed in the grade III and IV tumors (D).
(E) HIF-1a mRNA was also upregulated in high-grade tumors com-
pared to low-grade tumors. (F) TSP1 was highly expressed in high-
grade gliomas. (G) p53 was expressed more in high-grade than low-
grade gliomas and especially in anaplastic oligodendrogliomas (#11
and #12). (H) The result b-actin (530 bp) conﬁrmed the relative
amount and ﬁdelity of the total RNA samples. N, Normal brain tissue.
H.J. Kee et al. / FEBS Letters 569 (2004) 307–316 315cently, we reported that angiostatic BAI2 participated in is-
chemia-induced brain angiogenesis in concert with angiogenic
VEGF. The expression of BAI2 decreased in the ischemic side
of cerebral cortex after 1 h compared with sham-operated one
and the decreased level was maintained at 2 h, but was slowly
recovered after 8 h. Whereas, VEGF reached its peak level in
the ischemic cerebral cortex and contralateral non-ischemic
one after 8 h, but was returned to control level at 24 h [6].
Thus, BAI3 and VEGF showed reciprocal expression patterns
in in vivo focal ischemic model, just as BAI2 and VEGF do [6],
but BAI3 participated in the earlier phases of ischemia-induced
angiogenesis than BAI2. In the in vitro hypoxic model with
cobalt chloride, BAI3 mRNA expression decreased at 0.5 h
after hypoxia, but returned to the control value at 2 h and
decreased again at 8 h. In contrast, TSP1 mRNA increased at 2
h, but recovered to its basal level at 24 h after ischemia (data
not shown). These results indicate that BAI3 decreased earlier
than BAI2 and BAI1, but the expression pattern of TSP1 was
diﬀerent from that of BAI3. Lin et al. [24] reported that TSP1
and TSP2 are diﬀerently regulated after focal cerebral ische-
mia/reperfusion. The expression of TSP1 occurred early in a
biphasic fashion, while TSP2 was expressed in a delayed
monophasic manner. Collectively, among the three BAIs,
BAI3 seemed to act in the earlier phases of ischemia-induced
brain angiogenesis as well as an earlier antiangiogenic factor in
the development of the brain.
3.6. Changes in angiostatic and angiogenic genes in human
gliomas
We also examined the expression of angiostatic and angio-
genic genes in diﬀerent grades of tumors to study the rela-
tionship between BAIs and the progression of human gliomas.
We performed RT-PCR analyses of 17 human brain speci-
mens. The expression of BAI1 mRNA was observed in most
human gliomas except three cases of ependymomas (#4 and #5
ependymomas, #9 anaplastic ependymoma) (Fig. 8A). The
expression of BAI2 mRNA was lower in all grade III samples
compared to normal brain tissue, though the diﬀerence was
small (Fig. 8B). Also, the expression of BAI3 was lower in
grade III gliomas and IV glioblastoma compared with normal
brain (Fig. 8C). In particular, BAI3 was barely expressed in
ependymoma (#4) among low-grade and anaplastic ependy-
moma (#9) among grade III. Thus, our results indicated that
the expressions of BAI1, BAI2, and BAI3 mRNAs in low-
grade human gliomas were not changed compared with the
normal brain except for ependymomas (#4 and #5), and the
expression of BAI3 was generally lower in high-grade gliomas.
In contrast, normal brain and low-grade glioma did not ex-
press VEGF and HIF-1a except the ependymomas (#4 and
#5). However, VEGF expression was almost exclusively ob-
served in the grade III and IV tumors (Fig. 8D). In the ma-
jority of these high-grade tumors, upregulation of HIF-1a
mRNA above that of low-grade tumors, was also observed
(Fig. 8E). TSP1, a well-known angiostatic factor, was highly
expressed in high-grade tumors (Fig. 8F), indicating that the
regulation of TSPI was diﬀerent from that of BAIs in malig-
nant gliomas. Also, p53 was expressed more in high-grade than
in low-grade gliomas, especially in anaplastic oligodendro-
gliomas (#11 and #12) (Fig. 8G).
Glioblastoma represents 15–20% of brain tumors and 50%
of all gliomas [25]. VEGF is a hypoxia-inducible angiogenic
factor that is known to be upregulated in most cases of glio-blastomas. Kaur et al. [9] reported that BAI1 was widely ex-
pressed in normal brain but was absent in 28 glioma cell lines
and in the majority of human glioblastomas. In this study, we
examined whether the expressions of anti-angiogenic BAIs
diﬀered in diﬀerent grades of human gliomas. Expression of
BAI3 was generally decreased in malignant gliomas, whereas
angiogenic genes, such as VEGF and HIF-1a were increased.
In the real-time RT-PCR analyses, the relative expression
levels of BAI1 in normal brain tissue and SHSY5Y neuro-
blastoma cells were highest among BAIs, and the generally
decreased expressions of BAIs in high-grade glioma compared
to normal tissue (higher cycle-threshold values in high-grade
glioma than normal brain) were observed (data not shown)
[26]. Thus, the expression levels of three BAI genes in the brain
tumor tissues could be used for the prediction of malignancy.
However, TSP1 was expressed more in most human gliomas
than normal brain and showed a diﬀerent expression pattern
compared to BAIs. Sasaki et al. [27] reported that TSP1 se-
creted by malignant glioma cell lines participates in the
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it acts as an inhibitor of tumor growth, TSP1 is sometimes
expressed at high levels during tumor progression, suggesting
that tumors can eventually overcome its anti-tumor eﬀects [28].
Thus, our results indicate that brain-speciﬁc angiostatic BAIs
also may participate in the regulation of malignant progression
of gliomas, and suggest that BAIs may have more suppressive
eﬀects on brain tumor progression than TSP1.
The p53 tumor suppressor gene is frequently mutated in
human cancer, and is important in the pathogenesis of central
nervous system tumors [25]. Most of the mutations in the p53
gene occur in its DNA-binding domain. Every residue con-
tained in this domain (aa 110–286), with one exception, has
been found to be the target of substitutions in human cancers.
The most frequently mutated residues (R175, G245, R248,
R249, R273 and R282) account for about 30% of all known
mutations [29,30], In this study, p53 mRNA was highly ex-
pressed in grade III (anaplastic oligodendroma) and IV (glio-
blastoma) tumors, whereas BAIs were generally decreased in
these stages of glioma. Because BAI1 is induced by wild-type
p53 in cultured glial cells and pancreatic adenocarcinoma cells
[1,31], we examined whether there were reported or unknown
mutations of p53 in the malignant gliomas in which BAIs were
decreased or not expressed. We produced RT-PCR ampliﬁ-
cation products using primers ﬂanking the reported p53 point
mutation region (exon 5–7 and part of exon 8) from normal
tissue and human gliomas (ependymoma, anaplastic oligo-
dendroma and glioblastoma), and these fragments were se-
quenced (data not shown). Especially, besides the well-known
mutations, the sequence analysis of p53 from one ependy-
moma in which BAI1 and BAI3 were not expressed revealed
point mutations of 2 amino acids. This pair of p53 mutations
has not been previously reported: Arg72Pro (exon 5) and
Tyr220Cys (exon 6).
Collectively, our results indicated that neuron-speciﬁc BAI3
participates in the earlier phase of ischemia-induced brain
angiogenesis than BAI1 and BAI2, and brain-speciﬁc angio-
static BAIs were involved in the regulation of brain tumor
progression. The decreased level of three BAI genes in glioma
tissues could be used as one of the molecular markers for the
prediction of high-grade glioma.
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